Melanoma Management最新文献_第2页

Primary esophageal melanoma: a case report. 原发性食管黑色素瘤1例报告。

IF 3.6

Melanoma Management Pub Date : 2022-12-01 DOI: 10.2217/mmt-2022-0002

Pooja Patel, Colton Boudreau, Samuel Jessula, Madelaine Plourde

引用次数: 0

Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling. 葡萄膜黑色素瘤患者对使用基因表达谱进行预后检测的态度。

IF 3.6

Melanoma Management Pub Date : 2022-09-16 eCollection Date: 2022-09-01 DOI: 10.2217/mmt-2022-0003

Basil K Williams, Jennifer J Siegel, Katherina M Alsina, Lauren Johnston, Amanda Sisco, Kyleigh LiPira, Sara M Selig, Peter G Hovland

引用次数: 1

Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis. 成功的电化疗治疗大出血淋巴结黑色素瘤转移。

IF 3.6

Melanoma Management Pub Date : 2022-06-30 eCollection Date: 2022-06-01 DOI: 10.2217/mmt-2021-0006

Fredrik J Landström, Frida E Jakobsson, Stefan J Kristiansson

引用次数: 1

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma BRAF V600阴性晚期黑色素瘤双免疫检查点抑制剂与单免疫检查点抑制物相比总生存率提高

IF 3.6

Melanoma Management Pub Date : 2022-03-01 DOI: 10.2217/mmt-2021-0005

A. Kartolo, Cynthia Yeung, M. Kuksis, W. Hopman, T. Baetz

{"title":"Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma","authors":"A. Kartolo, Cynthia Yeung, M. Kuksis, W. Hopman, T. Baetz","doi":"10.2217/mmt-2021-0005","DOIUrl":"https://doi.org/10.2217/mmt-2021-0005","url":null,"abstract":"Aim: To evaluate the efficacy of dual versus single immune checkpoint inhibitors (ICI) in BRAF wild-type advanced melanoma patients. Materials & methods: A retrospective study of all advanced BRAF wild-type melanoma patients on palliative-intent ICI between 2015 and 2020 (n = 67). Results: Dual ICI had better overall survival (OS) when compared with single ICI in BRAF wild-type patients (hazard ratio: 0.204; 95% CI: 0.064–0.649; p = 0.007), but lost its statistical significance (median OSl not reached vs 20.9 months; p = 0.213; adjusted hazard ratio: 0.475; 95% CI: 0.164–1.380; p = 0.171) when only including patients treated after 2018 when dual ICI was funded in our province. Dual ICI were significantly associated with more frequent (p = 0.005) and severe (p = 0.026) immune-related adverse events, and required more immune-related adverse events-indicated systemic corticosteroid use (p < 0.001) compared with single ICI. Conclusion: While limited by small sample size and retrospective nature, dual ICI may have non statistically significant trend toward better OS efficacy when compared with single ICI in BRAF V600 wild-type advanced melanoma patients.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46747801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Knowledge and behavior of Lebanese parents regarding melanoma prevention in public and private school children 黎巴嫩家长在公立和私立学校儿童黑色素瘤预防方面的知识和行为

IF 3.6

Melanoma Management Pub Date : 2021-12-01 DOI: 10.2217/mmt-2021-0002

Léa El Haddad, Tarek Souaid, Diana Kadi, Joya-Rita Hindy, K. Souaid, H. Kourie, R. Tomb

引用次数: 0

Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments. 肺转移性黑色素瘤:诊断、影像学和治疗的现状。

IF 3.6

Melanoma Management Pub Date : 2021-07-09 eCollection Date: 2021-09-01 DOI: 10.2217/mmt-2021-0001

Kermit S Zhang, Tomer Pelleg, Sabrina Campbell, Catalina Rubio, Anthony Lukas Loschner, Susanti Ie

引用次数: 8

Evolving treatments and future therapeutic targets in desmoplastic melanoma. 结缔组织增生性黑色素瘤的新疗法和未来治疗靶点。

IF 3.6

Melanoma Management Pub Date : 2021-06-17 eCollection Date: 2021-09-01 DOI: 10.2217/mmt-2020-0013

Matthew J Hadfield, Alla Turshudzhyan, Jane M Grant-Kels

{"title":"Evolving treatments and future therapeutic targets in desmoplastic melanoma.","authors":"Matthew J Hadfield, Alla Turshudzhyan, Jane M Grant-Kels","doi":"10.2217/mmt-2020-0013","DOIUrl":"https://doi.org/10.2217/mmt-2020-0013","url":null,"abstract":"Desmoplastic melanoma (DM) is a rare and histopathologically distinct type of melanoma that is a subvariant of spindle cell melanoma [1]. It has a strong association with chronic sun exposure and usually occurs later in life. Incidence is reported to be less than four percent of cutaneous melanomas. Early diagnosis can be challenging because DM is predominantly dermal and often amelanotic [2]. The diagnosis can be difficult not only clinically but also histologically, as DM can be mistaken for a variety of benign and malignant nonmelanocytic spindle cell tumors. Histology of DM is divided into pure and mixed types, and this classification plays an important role in prediction of clinical outcomes [3]. Pure DM tends to have less potential for metastasis and as a result has a more favorable prognosis than mixed DM [4]. DM commonly demonstrates local invasion with poor circumscription due to its infiltrative nature which results in a high recurrence rate. It primarily affects patients with fair skin with age distribution of 60–80 years old and male-to-female ratio of two–one [5]. The overall survival for patients with DM is relatively favorable despite its depth at diagnosis with median survival at 5 and 10 years of 84.8 and 79.2 %, respectively [6]. Advanced age of the patient, higher stage of the tumor as well as increased Breslow depth were found to be independent positive factors associated with DM [7]. While established DM treatment options are surgical excision, sentinel lymph node biopsy, systemic chemotherapy and radiation therapy, a number of genetic mutations associated with DM have shown it to be responsive to targeted therapies. This review will focus on the future of DM therapy, which lies in better targeted therapy approaches and better penetration into the tumor core leading to more robust responses to therapeutic agents.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"8 3","pages":"MMT56"},"PeriodicalIF":3.6,"publicationDate":"2021-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/12/23/mmt-08-56.PMC8656346.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39582102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of rurality on melanoma diagnosis in Utah. 乡村性对犹他州黑色素瘤诊断的影响。

IF 3.6

Melanoma Management Pub Date : 2021-03-04 DOI: 10.2217/mmt-2020-0023

Tawnya L Bowles, Carol Sweeney, John Snyder, Jesse Gygi, Brad Bott, Daniel Wray, Timothy J Yeatman, William T Sause

引用次数: 2

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma. BRAF-MEK抑制剂在症状性颅内黑色素瘤检查点阻断治疗前作为类固醇保留桥。

IF 3.6

Melanoma Management Pub Date : 2021-02-15 DOI: 10.2217/mmt-2020-0022

Karam Khaddour, Tanner M Johanns, George Ansstas

引用次数: 2

Metastatic melanoma causing recurrent intussusception and perforation of small bowel: case reports and literature review. 转移性黑色素瘤引起复发性肠套叠和小肠穿孔:病例报告和文献复习。